Educated Guess to Accepted Practice: The Use of Oral AntiDiabetic Agents in Pregnancy
Oded Langer, MD, PhD
Please note: This is the complete reference list for the above article found on page 959 in
the print journal. For your convenience, a few of these references have been listed in the
article, too.
REFERENCES
1.
Piacquadio K, Hollingsworth DR, Murphy H: Effects of in-utero exposure to
oral hypoglycemic drugs. The Lancet 338:866-869, 1991
2.
Kemball ML, McIvert C, Milner RDG, et al. Neonatal hypoglycemia in
infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch
Dis Child 1970;45:696-701.
3.
Langer, O., Conway, D.L., Berkus, M.D., et al. A Comparison Glyburide
and Insulin in Women with Gestational Diabetes Mellitus. New England
Journal of Medicine, Vol. 343(16):1134-38, 2000.
4.
Reece EA, Homko C, Miodovnik M, et al. A consensus report of the
diabetes in pregnancy study group of North America Conference. J
Maternal-Fetal Neonatal Med. 2002;12:362–364
5.
Metzger BE, Buchanan TA, Coustan DR, de Leivia A, et al. Summary and
Recommendations of the Fifth International Workshop – Conference on
Gestational Diabetes Mellitus. Diabetes Care. July 2007; 30, ProQuest
Medical Library pg. S251.
6.
Gabbe SG, Graves CR. Management of diabetes mellitus complicating
pregnancy. Obstet Gynecol. 2003;102:857–868 and Greene MF. Oral
hypoglycemic drugs for gestational diabetes [editorial]. N Engl J Med.
2000;343:1178–1179
7.
Greene MF. Oral hypoglycemic drugs for gestational diabetes [editorial]. N
Engl J Med. 2000;343:1178–1179
8.
Koren G. The use of glyburide in gestational diabetes: an ideal example of
“bench to bedside.” Pediatr Res. 2001;49:734
9.
Saade G. Gestational diabetes mellitus: a pill or a shot? [ editorial] Obstet
Gynecol. 2005;105:456–457
10.
Durnwald C, Landon MB. Glyburide: The new alternative for treating
gestational diabetes? [editorial] Am J Obstet Gynecol 2005; 193, 1-2.
11.
Catalano PM, Tyzbit ED, Wolfe RR, et al: Carbohydrate metabolism
during pregnancy in control subjects and women with gestational diabetes.
Am J Physiol 264:E60-67, 1997
12.
Langer O. The diabetes in pregnancy dilemma. Leading change with
proven solutions. University Press of America 2006
13.
Pendergrass M, Fazioni E, DeFronzo RA: Non-insulin-dependent diabetes
mellitus and gestational diabetes mellitus: same disease, another name?
Diab Reviews 3:566-583, 1995
14.
UK prospective diabetes study 16. Overview of 6 years’ therapy of type II
diabetes: a progressive disease. UK Prospective Diabetes Study Group.
Diabetes 1995; 44:1249-58.
15.
American Diabetes Association: Implications of the United Kingdom
Prospective Diabetes Study. Diabetes Care 23:S27-31, 2000 (suppl 2)
16.
Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999.
7:139-53
17.
Kim C, Newton KM, Knopp RH: Gestational diabetes and the incidence of
type 2 diabetes. Diabetes Care 25:1862-68, 2002
18.
Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic
beta-cell function and prevention of type 2 diabetes by pharmacological
treatment of insulin resistance in high risk Hispanic women. Diabetes
51:2796-2803, 2002
19.
DeFronzo RA, Simonson DC. Oral sulfonylurea agents suppress hepatic
glucose production in non-insulin-dependent diabetic individuals. Diabetes
Care 1984;7:72-80.
20.
Rossetti L, Giaaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care
1990; 13:610-30
21.
Simonson DC, Farrannini E, Bevilacqua S, et al. Mechanism of
improvement in glucose metabolism after chronic glyburide therapy.
Diabetes Care 1984;33:838-45
22.
Zharikova O, Ravindran S, Nanovskaya T, et al. The kinetics for glyburide
metabolism by human and baboon livers and placentas. Am J obstet
Gynecol 2006; 195(6): S185 (Abs).
23.
Yogev Y, Ben-Haroush A, Chen R, et al. Undiagnosed asymptomatic
hypoglycemia: Diet, insulin, and glyburide for gestational diabetic
pregnancy. Obstet Gynecol 2004; 104:88-93
24.
Krentz AJ, Bailey CJ. Oral Antidiabetic Agents: Current role in type 2
diabetes mellitus. Drugs 2005; 65(3):385-411
25.
Turner RC, Cull CA, Fright V, et al. Glycemic control with diet,
sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus:
progressive requirement for multiple therapies. J Am Med Assoc 1999;
281:2005-12
26.
Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes.
BMJ 2000; 321:252-3
27.
Yki-Jarvinen H Thiazolidinedions. N Engl J Med 2004; 351:1106-18
28.
Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of
diabetes. Diabetes Revs 1998; 6:132-45
29.
Cortez J, Tarsa M, Agent S, et al. Randomized controlled trial of acarbose
vs. placebo in the treatment of gestational diabetes. Am J Obstet Gynecol
2006; 195(6):S149 (Abs).
30.
Enders AC, Blakenship TN: Comparative placental structure. Adv Drug
Del Rev 38:3-16, 1999
31.
Benirschke K, Kaufmann P, Baergen R. Human Placenta. Springer, New
York 2006
32.
Elliot B, Langer O, Schenker S, et al: Insignificant transfer of glyburide
occurs across the human placenta. Am J Obstet Gynecol 165:807-812,
1991
33.
Elliot B, Schenker S, Langer O, et al: Comparative placental transport of
oral hypoglycemic agents. A model of human placental drug transfer. Am
J Obstet Gynecol 171:653-660, 1994
34.
Elliot B, Langer O, Schussling F. A model of human placental drug
transfer. Am J Obstet Gynecol 1997;176:527-30
35.
Koren G: Glyburide and fetal safety: transplacental pharmacokinetic
considerations. Reprod Toxicol 15:225-229, 2001
36.
Nanovskaya TN, Nekhayeva, Hankins G, et al. (2006). Effect of human
serum albumin on transplacental transfer of glyburide. Biochemical
Pharmacology 72; 632-9
37.
Kraemer J, Klein J, Lubetsky A, et al. Perfusion studies of glyburide
transfer across the human placenta: Implications for fetal safety. (2006).
Am J Obstet Gynecol 195, 270-4.
38.
Gedeon C, Behravan J, Koren G, et al. Transport of glyburide by placental
ABD Transporters: Implications in fetal drug exposure. Placenta 2006. 27;
1096
39.
Langer O. Oral hypoglycemic agents and the pregnant diabetic: “From
bench to bedside.”Seminars in Perinat 2002; 26(3):215-24.
40.
Langer O. Oral hypoglycemic agents in pregnancy: Their time has come. J
Maternal-Fetal and Neonatal Med 2002; 12: 376-83
41.
Langer O. Oral Anti-Hyperglycemic Agents for the Management of
Gestational Diabetes Mellitus. Obstet Gynecol Clin N Am. 34 (2007) 255274.
42.
Nanovskaya TN, Nekhayeva IA, Patrikeeva SL, et al. Transfer of
metformin across the dually perfused human placental lobule. Am J
Obstet Gynecol 2006; 195:1081-5
43.
Kovo M, Haroutiunian S, Feldman N, et al. Determination of metformin
transfer across the human placenta using dually perfused ex-vivo
placental cotyledon model. [abstract] Am J Obstet Gynecol December
2005;193(6): S85
44.
Hague WM, Davoren PM, McIntyre D, et al. Metformin crosses the
placenta: a modulator for fetal insulin resistance? BMJ 2004; 327:880-1
45.
Vavky E, Zahlsen K, Spigset O, et al. Placental passage of metformin in
women with polycystic ovary syndrome. Fertil Steril 2005; 83:1575-8
46.
Hale TW, Kristensen JH, Hacket LP, et al. Transfer of metformin into
human milk. Diabetologia 2002; 45:1509-14
47.
Gardiner SJ, Kirkpatrick CM, Begg EJ, et al. Transfer of metformin into
human milk. Clin Pharmacol Therap 2003; 73: 71-7.)
48.
Sevillano J, Lopez-Perez IC, Herrera E, et al. Englitazone administration
to late pregnant rats produces delayed body growth and insulin resistance
in their fetuses and neonates. Biochem J 2005; 389, 913-8
49.
Chan LYS, Yeung JH, Lau TK. Placental transfer of rosiglitazone in the
first trimester of human pregnancy. Fertil Steril 2005; 83(4):955-8
50.
Holmes HJ, Casey BM, Bawdon RE. Placental transfer of rosiglitazone in
the ex vivo human perfusion model. Am J Obstet Gynecol 2006; 195,
1715-9
51.
Patrikeeva S, Hemauer S, Nanovskaya T, Hankins G, Mahmoud A.
Transplacental transfer and distribution of rosiglitazone. Am J Obstet
Gynecol 2006; 195(6); S128 (Abs.)
52.
Notelowitz M. Sulfonylurea therapy in the treatment of the pregnant
diabetic. S A Med J 1971; 45:226-9
53.
Towner D, Kjos SL, Montoro MM, et al: Congenital malformations in
pregnancies complicated by NIDDM. Diabetes Care 18:1446-1451, 1995
54.
Langer O, Conway D, Berkus M, et al. There is no association between
hypoglycemic use and fetal anomalies. Am J Obstet Gynecol 1999; 180(1)
(Abst): S38
55.
Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester
exposure to metformin: a meta-analysis. Fertil and Steril 2006; 86(3):65863
56.
Glueck et al (Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy
throughout pregnancy reduces the development of gestational diabetes in
women with polycystic ovary syndrome. Fertil Steril 2002; 77: 520-5
57.
Jakubwicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on
early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrin
Metab 2002; 87:524-9
58.
Moore L, Clokey D, Briery C, et al. Metformin use in gestational diabetes:
efficacy and maternal and neonatal outcomes. Am J Obstet Gynecol 2006;
195(6); S142 (Abs.)
59.
Langer, O. Conway, D.L.: Level of Glycemia and Perinatal Outcome in
Pregestational Diabetes. Journal of Maternal-Fetal Medicine. Vol
9,(1):35-41; Aug 2001
60.
Langer O. A Spectrum of Glucose Thresholds May Effectively Prevent
Complications in The Pregnant Diabetic Patient. Seminars of
Perinatology vol. 26; no. 3 (June) 2002: pp 196-205
61.
Langer O, Rodriguez DA, Xenakis EMJ, et al: Intensified vs. conventional
management of gestational diabetes. Am J Obstet Gynecol 170:10361047, 1994
62.
Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycemic agents in
118 diabetic pregnancies. Diabetic Med 2000; 17:507-11
63.
Lim JM, Tayob Y, O'Brien PM, et al. A comparison between the pregnancy
outcome of women with gestation diabetes treated with glibenclamide and
those treated with insulin. Med J Malaysia. 1997;52(4):377-81
64.
Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of
gestational diabetes: the San Antonio experience. J Matern Fetal Neonatal
Med. 2004; 15(1):51-5
65.
Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am
J Obstet Gynecol. 2004; 190(5):1438-9
66.
Chmait R, Dinise T, Moore T.: Prospective observational study to establish
predictors of glyburide success in women with gestational diabetes
mellitus. J Perinat 2004;24:617-22
67.
Gilson G, Murphy N. Comparison of oral glyburide with insulin for the
management of gestational diabetes mellitus in Alaskan native women.
Am J Obstet Gynecol 2002, 187;6, S152
68.
Velazquez MD, Bolnick J, Cloakey D. The use of glyburide in the
management of gestational diabetes. Obstet & Gynecol 2003; 101 (4)
suppl. 88S
69.
Kahn BF, Davies JK, Lynch AM, et al. Predictors of glyburide failure in the
treatment of gestational diabetes. Obst & Gynecol 107(6); 2006; 1303-09
70.
Jacobson GF, Ramos G, Ching J, et al. Comparison of glyburide and
insulin for the management of gestational diabetes in a large managed
care organization. Am J Obstet Gynecol (2005); 193, 118-24
71.
Bertini AM, Silva JC, Taborda W, et al. Perinatal outcomes and the use of
oral hypoglycemic agents. J Perinat Med (2005); 33; 519
72.
Rochon M, Rand L, Roth L, et al. Glyburide for the management of
gestational diabetes: Risk factors predictive of failure and associated
pregnancy outcomes. Am J Obstet Gynecol (2006); 195, 1090-4
73.
Langer O, Most O, Monga S. Glyburide: Predictors of treatment failure in
Gestational Diabetes. Am J Obstet Gynecol 2006; 195(6); S136 (Abs.) .
74.
Langer, O, Yogev, Y, Xenakis, E , et al: Insulin and glyburide therapy:
Dosage, severity level of gestational diabetes, and pregnancy outcome.
Am J Obstet Gynecol. 2005 Jan;192(1):134-9.
75.
Langer O, Yogev Y, Xenakis E, et al. Overweight and obese in gestational
diabetes: The impact on pregnancy outcome. Am J Obstet Gynecol
(2005). 192, 1768-76
76.
Langer O, Monga S, Most O. Obese gestational diabetic women:
Comparison of insulin and glyburide therapies. Am J Obstet Gynecol
2006; 195(6); 136S (Abs.).
77.
Goetzel L, Wilkins I. Glyburide compared to insulin for the treatment of
gestational diabetes mellitus: a cost analysis. J Perinatol. 2002;22:403–
406.